103 patents
Page 3 of 6
Utility
Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
21 Dec 21
The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
Rahul Godawat, Daniel Cummings, Veena Warikoo
Filed: 23 Dec 19
Utility
Anti-αβTCR antibody
30 Nov 21
The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
Filed: 10 Jan 18
Utility
mu419bkh5r p857sz0gcotfu3ld7wtw
2 Nov 21
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Z. Avila, Qun Zhou
Filed: 6 Aug 18
Utility
a0mqwqu3bthjv75ar98wqxcgo589u4nj0ph1ah5hf
12 Oct 21
The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR).
Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
Filed: 30 Oct 14
Utility
v5ttmr0zfr79akswvx3ykcrz4 rt2b5
28 Sep 21
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide.
Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
Filed: 3 Jan 19
Utility
zyp7e5fwdailymu3p8gr1esk1trc8y
14 Sep 21
Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient.
Sarah Moreno, Nikolai Bukanov, Timothy E. Weeden
Filed: 15 Nov 16
Utility
4s76uuebbd4pfw1f9vw1pu3jwa1s90eakuq9o0tb2t4fo9c7kdhk
7 Sep 21
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed.
Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
Filed: 4 Jan 19
Utility
iwg7w61fhuzqpje38liejeu9rjzpe2fk7ta99gjggmbel6l5kus21hztzk1g
31 Aug 21
The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs).
Timothy E. Weeden, Carol A. Nelson, Bruce M. Wentworth, Nicholas P. Clayton, Andrew Leger
Filed: 1 Feb 19
Utility
v8ioxn44 kyu5q7gas0n5k
31 Aug 21
Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708.
Catherine O'Riordan, Matthew Adamowicz
Filed: 3 Jul 19
Utility
msm1brw5f0ukte58jd0glp6r4ok90xfpmnd8wqqg1v41 57978u
24 Aug 21
Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
Filed: 1 Oct 19
Utility
vm2e4s60 6weuudad1t72l2aop2gku7triu9qjwsc
17 Aug 21
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
Filed: 7 Dec 16
Utility
ei6de99ikj4vgh5akdenvt1e1oq1p7r0ssp69v88kvada14fkhny3
10 Aug 21
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described.
Alejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
Filed: 29 Jan 19
Utility
8zmcpjuzsup5poeawa2fxu9d2sokj25v
10 Aug 21
The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins.
Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
Filed: 20 Nov 18
Utility
r4biflu4h3j7cj7vu gavlm
20 Jul 21
Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
Christopher Morgan, Xiaokui Zhang
Filed: 11 Jan 19
Utility
03wzft3drv0z3zxh78ft
13 Jul 21
Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods.
Agata Villiger-Oberbek, Jianguo Yang, Yang Yang, Gabrielle Lorenzo
Filed: 5 Jun 15
Utility
5574tlc3g71p 9ezf4fv12si
8 Jun 21
The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
Filed: 19 Oct 17
Utility
ryw ljw2fezkxket228agelsfxbswue
18 May 21
Elyse Bourque, Mario A. Cabrera-Salazar, Cassandra Celatka, Seng H. Cheng, Bradford Hirth, Andrew Good, Katherine Jancsics, John Marshall, Markus Metz, Ronald K. Scheule, Renato Skerlj, Yibin Xiang, Zhong Zhao, John Leonard, Thomas Natoli, Elina Makino, Herve Husson, Oxana Beskrovnaya
Filed: 18 Apr 17
Utility
nmolhe1kh3aisu1l6dkgg1buexktgp1w4qpbqciywfvhbzo5lexm52x
4 May 21
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
Filed: 18 Mar 15
Utility
cwby w2kjx1fzqtv4zuem53shvezbiemloabzje0l25iwwrs9hwbr4ffd
13 Apr 21
Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described.
Yunxiang Zhu
Filed: 12 Jun 19
Utility
w1h26ibdau3gb1duoe7cry4 y4dfxevk1i5o5vfnt1tq6n7ks
6 Apr 21
Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit.
Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
Filed: 15 Aug 17